Pediatric Asthma: Where Has Montelukast Gone?

Coronavirus: Where Has All the Health Economics Gone?

As the coronavirus disease 2019 (COVID-19) pandemic continues to unfold there is an untold number of trade-offs being made in every country around the globe. The experience in the United Kingdom and Canada to date has not seen much uptake of health economics methods. We provide some thoughts on how this could take place, specifically in three areas. Firstly, this can involve understanding the i...

Where Has My Time Gone?

Time matters. In a networked world, we would like mobile devices to provide a crisp user experience and applications to instantaneously return results. Unfortunately, application performance does not depend solely on processing time, but also on a number of different components that are commonly counted in the overall system latency. Latency is more than just a nuisance to the user, poorly acco...

Where has the air gone?

Arch Dis Child January 2011 Vol 96 No 1 Pneumorrhachis (air within the spinal canal) is rare and usually associated with other air leaks. Diagnosis is usually by high resolution CT scan. A 9-year-old boy had a 10-day history of persistent cough despite treatment with inhaled bronchodilators, systemic steroids and antibiotics before coming to hospital. Physical examination demonstrated good gene...

Montelukast in pediatric asthma management.

UNLABELLED Leukotriene modifiers (receptor antagonist and biosynthesis inhibitor) represent the first mediator specific therapeutic option for asthma. Montelukast, a leukotriene receptor antagonist is the only such agent approved for use in pediatric patients. Montelukast modifies action of leukotrienes, which are the most potent bronchoconstrictors, by blocking Cysteinyl leukotriene receptors....

Where has all the money gone?